139 related articles for article (PubMed ID: 37787151)
1. Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directions.
Herrity E; Pereira MP; Kim DDH
Br J Haematol; 2023 Dec; 203(5):722-735. PubMed ID: 37787151
[TBL] [Abstract][Full Text] [Related]
2. Treatment of AML Relapse After Allo-HCT.
Webster JA; Luznik L; Gojo I
Front Oncol; 2021; 11():812207. PubMed ID: 34976845
[TBL] [Abstract][Full Text] [Related]
3. Novel strategies to prevent relapse after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes.
Kekre N; Koreth J
Curr Opin Hematol; 2015 Mar; 22(2):116-22. PubMed ID: 25575033
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.
Al-Shaibani E; Novitzky-Basso I; Mattsson J; Kim DDH
Int J Hematol; 2023 Jul; 118(1):1-17. PubMed ID: 37212948
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
[TBL] [Abstract][Full Text] [Related]
6. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.
Zuanelli Brambilla C; Lobaugh SM; Ruiz JD; Dahi PB; Goldberg AD; Young JW; Gyurkocza B; Shaffer BC; Ponce DM; Tamari R; Sanchez Escamilla M; Castillo Flores N; Politikos I; Scordo M; Shah GL; Cho C; Lin RJ; Maloy MA; Devlin SM; Jakubowski AA; Berman E; Stein EM; Papadopoulos EB; Perales MA; Tallman MS; Giralt SA; Smith M
Transplant Cell Ther; 2021 Sep; 27(9):771.e1-771.e10. PubMed ID: 34033977
[TBL] [Abstract][Full Text] [Related]
7. Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion.
Shah N; Rakszawski K; Nickolich M; Ehmann C; Wirk B; Naik S; Rybka W; Zheng H; Mierski J; Silar B; Mackey G; Greiner R; Brown V; Claxton D; Mineishi S; Minagawa K
Ann Hematol; 2021 Oct; 100(10):2585-2592. PubMed ID: 34322774
[TBL] [Abstract][Full Text] [Related]
8. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Heinicke T; Krahl R; Kahl C; Cross M; Scholl S; Wolf HH; Hähling D; Hegenbart U; Peter N; Schulze A; Florschütz A; Schmidt V; Reifenrath K; Zojer N; Junghanss C; Sayer HG; Maschmeyer G; Späth C; Hochhaus A; Fischer T; Al-Ali HK; Niederwieser D
Ann Hematol; 2021 Sep; 100(9):2387-2398. PubMed ID: 34232360
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
11. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy.
Sauerer T; Velázquez GF; Schmid C
Mol Cancer; 2023 Nov; 22(1):180. PubMed ID: 37951964
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT).
Konuma T; Yanada M; Yamasaki S; Kuwatsuka Y; Fukuda T; Kobayashi T; Ozawa Y; Uchida N; Ota S; Hoshino T; Takahashi S; Kanda Y; Ueda Y; Takanashi M; Kanda J; Ichinohe T; Atsuta Y; Yano S
Br J Haematol; 2018 Jul; 182(2):245-250. PubMed ID: 29808919
[TBL] [Abstract][Full Text] [Related]
13. Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation.
Zeiser R; Beelen DW; Bethge W; Bornhäuser M; Bug G; Burchert A; Christopeit M; Duyster J; Finke J; Gerbitz A; Klusmann JH; Kobbe G; Lübbert M; Müller-Tidow C; Platzbecker U; Rösler W; Sauer M; Schmid C; Schroeder T; Stelljes M; Kröger N; Müller LP
Biol Blood Marrow Transplant; 2019 Apr; 25(4):e128-e140. PubMed ID: 30658222
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients.
Al-Shaibani E; Bautista R; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Gerbitz A; Pasic I; Mattsson J; Michelis FV
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e327-e334. PubMed ID: 34866020
[TBL] [Abstract][Full Text] [Related]
15. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
16. Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
Finke J; Schmoor C; Stelljes M; Burchert A; Dreger P; Hegenbart U; Wagner-Drouet EM; Bornhäuser M; Sohlbach K; Schub N; Reicherts C; Kobbe G; Glass B; Bertz H; Grishina O
Bone Marrow Transplant; 2022 Nov; 57(11):1664-1670. PubMed ID: 35982219
[TBL] [Abstract][Full Text] [Related]
17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
[TBL] [Abstract][Full Text] [Related]
19. Reducing Mortality of Single-Unit Unrelated Cord Blood Transplantation for Relapsed Acute Myeloid Leukemia after a Previous Allogeneic Transplantation: A Real-World Retrospective Study Over the Past 19 Years in Japan.
Konuma T; Mizuno S; Harada K; Uchida N; Takahashi S; Eto T; Ota S; Kobayashi H; Katayama Y; Mori Y; Maruyama Y; Onizuka M; Yonezawa A; Kawakita T; Kimura T; Kanda Y; Fukuda T; Atsuta Y; Yanada M;
Transplant Cell Ther; 2022 Nov; 28(11):777.e1-777.e11. PubMed ID: 35964936
[TBL] [Abstract][Full Text] [Related]
20. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.
Wudhikarn K; Brunstein CG; Bachanova V; Burns LJ; Cao Q; Weisdorf DJ
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1497-504. PubMed ID: 21338707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]